HRP20151021T1 - Formulacije na osnovi nalbufina i njihove uporabe - Google Patents
Formulacije na osnovi nalbufina i njihove uporabe Download PDFInfo
- Publication number
- HRP20151021T1 HRP20151021T1 HRP20151021TT HRP20151021T HRP20151021T1 HR P20151021 T1 HRP20151021 T1 HR P20151021T1 HR P20151021T T HRP20151021T T HR P20151021TT HR P20151021 T HRP20151021 T HR P20151021T HR P20151021 T1 HRP20151021 T1 HR P20151021T1
- Authority
- HR
- Croatia
- Prior art keywords
- nalbuphine
- pharmaceutical formulation
- oral pharmaceutical
- povidone
- hcl
- Prior art date
Links
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 title claims 7
- 229960000805 nalbuphine Drugs 0.000 title claims 7
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 8
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 7
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 229940069328 povidone Drugs 0.000 claims 5
- 239000000454 talc Substances 0.000 claims 5
- 229910052623 talc Inorganic materials 0.000 claims 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 235000019359 magnesium stearate Nutrition 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 239000000377 silicon dioxide Substances 0.000 claims 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 3
- 229920003081 Povidone K 30 Polymers 0.000 claims 3
- 229960000913 crospovidone Drugs 0.000 claims 3
- 239000000796 flavoring agent Substances 0.000 claims 3
- 235000019634 flavors Nutrition 0.000 claims 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 claims 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000026251 Opioid-Related disease Diseases 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 claims 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 claims 1
- 235000013736 caramel Nutrition 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 229960001375 lactose Drugs 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
1. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 30 mg, koja sadrži po masi:
- 4,69 % nalbufina/HCl,
- 54,58 % manitola,
- 37,8 % povidona,
- 2% krospovidona,
- 0,10 % koloidne anhidridne silike,
- 0,50 % natrijevog stearil-fumarata,
- 0,33 % talka.
2. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 30 mg, koja sadrži po masi:
- 18,65 % nalbufina/HCl,
- 48 % aglomeriranog α-laktoza-monohidrata (Tablettose® 80),
- 14 % mikrokristalne celuloze (Avicel® PH200),
- 4,50 % povidona,
- 2,25% krospovidona,
- 0,45 % koloidne anhidridne silike,
- 0,45 % magnezijevog stearata,
- 2,70 % talka,
- 9 % Sepifilm® LP014.
3. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 10 mg, koja sadrži po masi:
- 11,86 % nalbufina/HCl,
- 53,28 % aglomeriranog α-laktoza-monohidrata (Tablettose® 80),
- 18,43 % mikrokristalne celuloze (Avicel® PH200),
- 4,56 % povidona (PVP K30),
- 0,46 % silike (Aerosil® 200),
- 0,46 % magnezijevog stearata,
- 1,83 % talka,
- 9,13 % Sepifilm® LP014.
4. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 50 mg, koja sadrži po masi:
- 20,55 % nalbufina/HCl,
- 22,02 % laktoze,
- 47,53 % mikrokristalne celuloze (Avicel® PH200),
- 4,98 % povidona (PVP CL),
- 0,50 % magnezijevog stearata,
- 3,98 % arome,
- 0,44 % Sepifilm® IR777.
5. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku granulata od 10 mg, koji sadrži po masi:
- 1,99 % nalbufina/HCl,
- 27,80 % polietilen glikola (PEG 400),
- 21,29 % magnezijevog aluminosilikata (Neusilin® UFL2),
- 6,49 % povidona K30,
- 0,50 % talka,
- 3,69 % suklraloze (zaslađivača),
- 29,20 % arome za maskiranje okusa,
- 2,56 % okusa karamele,
- 6,49 % Sepifilm® LP014.
6. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da je u obliku tablete od 30 mg, koja sadrži po masi:
- 20,31 % nalbufina/HCl,
- 62,16 % aglomeriranog α-laktoza-monohidrata (Tablettose® 80),
- 6,65 % povidona (PVP K30),
- 2,38% krospovidona (Polyplasdone XL),
- 1,76 % mikrokristalne celuloze (Avicel® PH200),
- 0,10 % silike (Aerosil® 200),
- 0,48 % magnezijevog stearata,
- 1,92 % talka,
- 4,81 % Sepifilm® LP014.
7. Oralna farmaceutska formulacija s trenutnim otpuštanjem, naznačena time, da ona odgovara prema bilo kojem od zahtjeva 1 do 6, te se takva upotrebljava u obradi bolova koji se generiraju putem liječenja ovisnosti od opijata.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1056689A FR2963889B1 (fr) | 2010-08-20 | 2010-08-20 | Formulations a base de nalbuphine et leurs utilisations |
| PCT/FR2011/051929 WO2012022919A2 (fr) | 2010-08-20 | 2011-08-18 | Formulations à base de nalbuphine et leurs utilisations |
| EP11758519.0A EP2605757B1 (fr) | 2010-08-20 | 2011-08-18 | Formulations a base de nalbuphine et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151021T1 true HRP20151021T1 (hr) | 2015-11-06 |
Family
ID=43426302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151021TT HRP20151021T1 (hr) | 2010-08-20 | 2015-09-28 | Formulacije na osnovi nalbufina i njihove uporabe |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20130123294A1 (hr) |
| EP (1) | EP2605757B1 (hr) |
| JP (2) | JP2013534242A (hr) |
| KR (1) | KR101801424B1 (hr) |
| CN (1) | CN103025317B (hr) |
| AR (1) | AR082493A1 (hr) |
| AU (1) | AU2011290614B2 (hr) |
| BR (1) | BR112013004016A2 (hr) |
| CA (1) | CA2804333C (hr) |
| CL (1) | CL2013000477A1 (hr) |
| CY (1) | CY1116729T1 (hr) |
| DK (1) | DK2605757T3 (hr) |
| EA (1) | EA024945B1 (hr) |
| ES (1) | ES2548535T3 (hr) |
| FR (1) | FR2963889B1 (hr) |
| HR (1) | HRP20151021T1 (hr) |
| HU (1) | HUE027664T2 (hr) |
| IL (1) | IL224230A (hr) |
| MA (1) | MA34484B1 (hr) |
| MX (1) | MX354416B (hr) |
| NZ (1) | NZ605469A (hr) |
| PH (1) | PH12013500289A1 (hr) |
| PL (1) | PL2605757T3 (hr) |
| PT (1) | PT2605757E (hr) |
| RS (1) | RS54244B1 (hr) |
| SG (1) | SG187566A1 (hr) |
| SI (1) | SI2605757T1 (hr) |
| SM (1) | SMT201500257B (hr) |
| TW (1) | TWI522100B (hr) |
| UA (1) | UA110945C2 (hr) |
| WO (1) | WO2012022919A2 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| KR20220044385A (ko) * | 2012-12-14 | 2022-04-07 | 트레비 테라퓨틱스, 인코포레이티드 | 소양증을 치료하는 방법 |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| CN105560202B (zh) * | 2016-03-11 | 2019-05-24 | 广州玻思韬控释药业有限公司 | 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用 |
| CA3106995A1 (en) | 2018-07-23 | 2020-01-30 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness, or dyspnea with nalbuphine compositions |
| SG11202102504WA (en) | 2018-09-14 | 2021-04-29 | Cara Therapeutics Inc | Oral formulations of kappa opioid receptor agonists |
| AU2021236662A1 (en) | 2020-03-18 | 2022-11-10 | Cara Therapeutics, Inc. | Oligosaccharide formulations of kappa opioid receptor agonists |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282215A (en) * | 1980-06-17 | 1981-08-04 | E. I. Du Pont De Nemours And Company | Analgesic mixture of nalbuphine and acetylsalicylic acid, derivative or salt thereof |
| US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4366159A (en) * | 1981-09-08 | 1982-12-28 | Michael Richard Magruder | Nalbuphine-narcotic analgesic composition and method of producing analgesia |
| US4477457A (en) * | 1982-10-28 | 1984-10-16 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia using nalmetrene |
| US6210714B1 (en) * | 1993-11-23 | 2001-04-03 | Euro-Celtique S.A. | Immediate release tablet cores of acetaminophen having sustained-release coating |
| FI972718A0 (fi) | 1996-07-02 | 1997-06-24 | More Magic Software Mms Oy | Foerfaranden och arrangemang foer distribution av ett anvaendargraenssnitt |
| US6372254B1 (en) * | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| EP1117389A1 (en) | 1998-09-08 | 2001-07-25 | TheraTech, Inc. | Method of making pressure sensitive adhesive matrix patches containing hydrophilic salts of drugs |
| JP2001089373A (ja) * | 1999-09-24 | 2001-04-03 | Tanabe Seiyaku Co Ltd | 経口投与製剤 |
| JP2003516353A (ja) * | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | ヴァルデコキシブ組成物 |
| KR20010107754A (ko) * | 2000-05-26 | 2001-12-07 | 민경윤 | 경구투여용 속용정의 제조 방법 |
| US7323192B2 (en) * | 2001-09-28 | 2008-01-29 | Mcneil-Ppc, Inc. | Immediate release tablet |
| US6680067B2 (en) | 2001-11-26 | 2004-01-20 | Oliver Yoa-Pu Hu | Controlled-release pharmaceutical preparation containing nalbuphine and a process for preparing the same |
| RU2254852C1 (ru) | 2004-01-23 | 2005-06-27 | Ефим Давыдович Нежинский | Раствор для инъекций, обладающий выраженным анальгетическим действием, и способ его получения |
| US8394812B2 (en) * | 2005-08-24 | 2013-03-12 | Penwest Pharmaceuticals Co. | Sustained release formulations of nalbuphine |
| JP2009506059A (ja) | 2005-08-24 | 2009-02-12 | ペンウエスト ファーマシューティカルズ カンパニー | ナルブフィンの徐放性製剤 |
| EP2018178A4 (en) * | 2006-04-25 | 2009-12-16 | Michael Victor Voronkov | ADMINISTRATION OF AN AGONIST-ANTAGONIST COMPLEX TO PATIENTS WITH OPIOID DEPENDENCE |
| WO2008074098A1 (en) * | 2006-12-21 | 2008-06-26 | Alphapharm Pty Ltd | Pharmaceutical composition |
| US20080207667A1 (en) * | 2007-02-23 | 2008-08-28 | Rhame Robert W | Use of nalbuphine and related compounds to treat symptoms of respiratory problems |
| AU2010206724A1 (en) * | 2009-01-22 | 2011-07-28 | Nanotherapeutics, Inc. | Process for preparing particles of opioids and compositions produced thereby |
| WO2011041414A1 (en) * | 2009-09-30 | 2011-04-07 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
-
2010
- 2010-08-20 FR FR1056689A patent/FR2963889B1/fr not_active Expired - Fee Related
-
2011
- 2011-08-18 AU AU2011290614A patent/AU2011290614B2/en not_active Ceased
- 2011-08-18 DK DK11758519.0T patent/DK2605757T3/en active
- 2011-08-18 KR KR1020137002467A patent/KR101801424B1/ko active IP Right Grant
- 2011-08-18 PH PH1/2013/500289A patent/PH12013500289A1/en unknown
- 2011-08-18 CA CA2804333A patent/CA2804333C/fr not_active Expired - Fee Related
- 2011-08-18 WO PCT/FR2011/051929 patent/WO2012022919A2/fr active Application Filing
- 2011-08-18 BR BR112013004016A patent/BR112013004016A2/pt not_active IP Right Cessation
- 2011-08-18 JP JP2013524474A patent/JP2013534242A/ja active Pending
- 2011-08-18 SG SG2013004379A patent/SG187566A1/en unknown
- 2011-08-18 MX MX2013001985A patent/MX354416B/es active IP Right Grant
- 2011-08-18 PL PL11758519T patent/PL2605757T3/pl unknown
- 2011-08-18 UA UAA201303394A patent/UA110945C2/uk unknown
- 2011-08-18 US US13/810,358 patent/US20130123294A1/en not_active Abandoned
- 2011-08-18 PT PT117585190T patent/PT2605757E/pt unknown
- 2011-08-18 SI SI201130612T patent/SI2605757T1/sl unknown
- 2011-08-18 EP EP11758519.0A patent/EP2605757B1/fr active Active
- 2011-08-18 ES ES11758519.0T patent/ES2548535T3/es active Active
- 2011-08-18 RS RS20150601A patent/RS54244B1/en unknown
- 2011-08-18 HU HUE11758519A patent/HUE027664T2/en unknown
- 2011-08-18 MA MA35689A patent/MA34484B1/fr unknown
- 2011-08-18 NZ NZ605469A patent/NZ605469A/en not_active IP Right Cessation
- 2011-08-18 CN CN201180035176.5A patent/CN103025317B/zh not_active Expired - Fee Related
- 2011-08-18 EA EA201300258A patent/EA024945B1/ru not_active IP Right Cessation
- 2011-08-19 AR ARP110103019A patent/AR082493A1/es unknown
- 2011-08-19 TW TW100129750A patent/TWI522100B/zh not_active IP Right Cessation
-
2013
- 2013-01-15 IL IL224230A patent/IL224230A/en active IP Right Grant
- 2013-02-18 CL CL2013000477A patent/CL2013000477A1/es unknown
-
2015
- 2015-09-28 HR HRP20151021TT patent/HRP20151021T1/hr unknown
- 2015-09-29 CY CY20151100862T patent/CY1116729T1/el unknown
- 2015-10-20 SM SM201500257T patent/SMT201500257B/it unknown
-
2016
- 2016-04-20 JP JP2016084673A patent/JP6173521B2/ja not_active Expired - Fee Related
- 2016-06-01 US US15/170,033 patent/US10441585B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151021T1 (hr) | Formulacije na osnovi nalbufina i njihove uporabe | |
| US10653776B2 (en) | Compositions and methods for reducing overdose | |
| ES2660544T3 (es) | Liberación pulsátil de fármaco | |
| ES2694224T3 (es) | Comprimido de desintegración oral y procedimiento para producir el mismo | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| HRP20230691T1 (hr) | Farmaceutske formulacije koje sadrže dapagliflozin propilen glikol hidrat | |
| JP2009507048A5 (hr) | ||
| WO2010103544A4 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP2010522242A5 (hr) | ||
| CA2628200A1 (en) | Solid pharmaceutical compositions containing pregabalin | |
| YU19501A (sh) | Sistem za kontrolisano davanje lekova oralnim putem koji obezbeđuje vremensku i prostornu kontrolu | |
| CN104220050A (zh) | 包含包封于硬胶囊中的多单元球状片剂(must)的复合制剂及其制备方法 | |
| US20150250746A1 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| JP2012533565A5 (hr) | ||
| JP2007503414A5 (hr) | ||
| JP2006527256A5 (hr) | ||
| CN102573911B (zh) | 一种内含用以治疗神经退化性疾病的立即释出与长效释出药物的口服剂量配方 | |
| JP2019508464A (ja) | クロピドグレル及びアスピリンを含む複合製剤 | |
| JP2008531594A5 (hr) | ||
| JP2007182451A5 (hr) | ||
| KR101004205B1 (ko) | 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물 | |
| EP3169316A1 (en) | Compositions and methods for reducing overdose | |
| KR101497354B1 (ko) | 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물 | |
| US20190388354A1 (en) | Improved compositions and methods for reducing overdose | |
| GB2429645A (en) | Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent |